Vivos Therapeutics, Inc. (NASDAQ:VVOS) Sees Large Drop in Short Interest

Vivos Therapeutics, Inc. (NASDAQ:VVOS) was the recipient of a significant decline in short interest in the month of May. As of May 15th, there was short interest totalling 206,000 shares, a decline of 20.6% from the April 30th total of 259,400 shares. Currently, 4.5% of the company’s shares are sold short. Based on an average daily volume of 111,100 shares, the days-to-cover ratio is presently 1.9 days.

Institutional Investors Weigh In On Vivos Therapeutics

A number of large investors have recently added to or reduced their stakes in VVOS. Cutter & CO Brokerage Inc. purchased a new position in Vivos Therapeutics in the 4th quarter valued at about $163,000. Commonwealth Equity Services LLC boosted its holdings in Vivos Therapeutics by 23.8% in the fourth quarter. Commonwealth Equity Services LLC now owns 26,000 shares of the company’s stock valued at $112,000 after purchasing an additional 5,000 shares during the last quarter. Geode Capital Management LLC grew its stake in Vivos Therapeutics by 55.6% during the 4th quarter. Geode Capital Management LLC now owns 44,827 shares of the company’s stock valued at $192,000 after purchasing an additional 16,025 shares in the last quarter. Anson Funds Management LP purchased a new stake in Vivos Therapeutics during the 4th quarter worth approximately $1,041,000. Finally, EWA LLC acquired a new position in shares of Vivos Therapeutics in the 1st quarter valued at approximately $30,000. 26.35% of the stock is owned by institutional investors and hedge funds.

Vivos Therapeutics Price Performance

Shares of VVOS opened at $2.36 on Wednesday. The stock has a market cap of $13.90 million, a PE ratio of -0.42 and a beta of 7.31. Vivos Therapeutics has a 12 month low of $1.97 and a 12 month high of $6.28. The stock’s 50-day moving average is $2.51 and its two-hundred day moving average is $3.50.

Vivos Therapeutics (NASDAQ:VVOS) last issued its quarterly earnings data on Thursday, May 15th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.44) by ($0.01). The firm had revenue of $3.70 million during the quarter, compared to analyst estimates of $3.63 million. Vivos Therapeutics had a negative net margin of 86.19% and a negative return on equity of 335.04%. During the same period last year, the business earned ($1.63) EPS. On average, research analysts anticipate that Vivos Therapeutics will post -1.79 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities analysts recently commented on the stock. Wall Street Zen lowered shares of Vivos Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, May 22nd. Ascendiant Capital Markets lowered their price objective on shares of Vivos Therapeutics from $6.60 to $6.20 and set a “buy” rating for the company in a research note on Tuesday, April 15th. Alliance Global Partners lowered Vivos Therapeutics from a “buy” rating to a “neutral” rating in a research note on Tuesday, May 20th. Finally, Industrial Alliance Securities set a $2.25 price target on shares of Vivos Therapeutics in a research report on Tuesday, May 20th.

About Vivos Therapeutics

Vivos Therapeutics, Inc, a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring.